Early and Precise: Treating HRR Alterations in Hormone-Sensitive Prostate Cancer

Abstract Patients with prostate cancer and HRR alterations face worse outcomes. Early use of PARP inhibitors, especially in BRCA-mutated cancers is promising. However, optimal timing, sequencing, and benefits for non-BRCA alterations remain unclear, underscoring the need for well-designed clinical trials and personalized treatment discussions.